M
MINERALYS THERAPEUTICS, INC. COMMON STOCK
NASDAQ: MLYS (Mineralys Therapeutics, Inc.)
最近更新时间: 3小时之前15.52
-0.29 (-1.83%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Mineralys Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 价值 35% | -1.7 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | -1.7 |
| 时机 35% | -2.5 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | -2.5 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×1.25 |
| 不计入评分 | |
| 价格波动 参考 | 3.7 |
| 最终评分 | -2.23 |
|
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.40% |
| 机构持股比例 | 103.83% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Catalys Pacific, Llc | 30 Sep 2026 | 7,799,518 |
| Ra Capital Management, L.P. | 30 Jun 2026 | 7,692,750 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 5,871,018 |
| Deerfield Management Company, L.P. | 30 Jun 2026 | 3,958,000 |
| Laurion Capital Management Lp | 30 Sep 2026 | 2,481,698 |
| Orbimed Advisors Llc | 30 Jun 2026 | 2,110,300 |
| Capital World Investors | 30 Jun 2026 | 1,997,607 |
| Armistice Capital, Llc | 30 Jun 2026 | 1,736,000 |
| Troluce Capital Advisors Llc | 30 Jun 2026 | 1,728,753 |
该时间范围内无数据。
投资组合